Why is Evogene Ltd. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 48.20% and Operating profit at 3.49% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Jun 25
- NET SALES(HY) At USD 3.33 MM has Grown at -34.8%
- INTEREST(HY) At USD 1.09 MM has Grown at 279.17%
- CASH AND EQV(HY) Lowest at USD 21.54 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -34.13%, its profits have risen by 24.6%
4
Below par performance in long term as well as near term
- Along with generating -34.13% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Evogene Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Evogene Ltd.
-27.63%
-0.66
127.11%
S&P 500
13.22%
0.61
20.17%
Quality key factors
Factor
Value
Sales Growth (5y)
48.20%
EBIT Growth (5y)
3.49%
EBIT to Interest (avg)
-15.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.52
Sales to Capital Employed (avg)
-1.04
Tax Ratio
0.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.33%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.01
EV to EBIT
0.08
EV to EBITDA
0.09
EV to Capital Employed
0.14
EV to Sales
-0.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
174.95%
ROE (Latest)
Negative BV
12What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -17.73 MM
NET PROFIT(HY)
Higher at USD -5.9 MM
ROCE(HY)
Highest at 0%
RAW MATERIAL COST(Y)
Fallen by -558.57% (YoY
OPERATING PROFIT(Q)
Highest at USD -2.78 MM
-15What is not working for the Company
NET SALES(HY)
At USD 3.33 MM has Grown at -34.8%
INTEREST(HY)
At USD 1.09 MM has Grown at 279.17%
CASH AND EQV(HY)
Lowest at USD 21.54 MM
Here's what is working for Evogene Ltd.
Operating Cash Flow
Highest at USD -17.73 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -5.9 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -2.78 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Raw Material Cost
Fallen by -558.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Evogene Ltd.
Net Sales
At USD 3.33 MM has Grown at -34.8%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Interest
At USD 1.09 MM has Grown at 279.17%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Cash and Eqv
Lowest at USD 21.54 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






